Rani Therapeutics (NASDAQ:RANI – Get Rating) is one of 950 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Rani Therapeutics to similar businesses based on the strength of its earnings, valuation, profitability, risk, analyst recommendations, institutional ownership and dividends.
Earnings and Valuation
This table compares Rani Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Rani Therapeutics||$2.72 million||-$8.33 million||-8.61|
|Rani Therapeutics Competitors||$1.84 billion||$246.10 million||-3.83|
Rani Therapeutics’ competitors have higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
This table compares Rani Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rani Therapeutics Competitors||-3,217.78%||-161.38%||-24.46%|
This is a breakdown of current recommendations and price targets for Rani Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rani Therapeutics Competitors||3099||13031||39180||631||2.67|
Rani Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 148.03%. As a group, “Pharmaceutical preparations” companies have a potential upside of 96.10%. Given Rani Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than its competitors.
Risk and Volatility
Rani Therapeutics has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Rani Therapeutics’ competitors have a beta of 0.97, indicating that their average stock price is 3% less volatile than the S&P 500.
Rani Therapeutics beats its competitors on 8 of the 13 factors compared.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.